Bayer Aktiengesellschaft: management transactions · Germany · BaFin

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft (ISIN: DE000BAY0017) is a global life-science group listed on Xetra/Frankfurt (DAX/MDAX/SDAX), in Germany. The company was founded on August 1, 1863, in Barmen, now part of Wuppertal, and later shifted its corporate center to Leverkusen, where its global headquarters are located today. Bayer’s long industrial heritage, together with the Bayer Cross brand, has helped establish it as a globally recognized name in health, agriculture and, to a smaller extent, consumer protection products. ([bayer.com](https://www.bayer.com/en/history/1863-1881?utm_source=openai)) Bayer’s business model is built around three core divisions: Pharmaceuticals, Crop Science and Consumer Health. Pharmaceuticals focuses on prescription medicines, with strong positions in cardiology, women’s health, oncology, hematology, ophthalmology and radiology. Crop Science covers seeds, traits, chemical and biological crop protection, as well as digital tools for modern farming. Consumer Health markets over-the-counter products for self-care, including nutritional supplements, allergy, cough and cold, dermatology, pain relief and digestive health. ([bayer.com](https://www.bayer.com/sites/default/files/2025-03/bayer-annual-report-2024.pdf?utm_source=openai)) From a competitive standpoint, Bayer is one of the leading agricultural-input companies globally by sales, while also ranking among the major players in consumer health and specialty pharmaceuticals. Its geographic footprint is broad: the group operates in more than 80 countries and relies on a worldwide network of subsidiaries, production sites, research centers and commercial operations. Leverkusen remains strategically important as both headquarters and a key manufacturing and distribution hub for pharmaceutical products. ([bayer.com](https://www.bayer.com/en/this-is-bayer?utm_source=openai)) Key products and franchises include established prescription medicines, widely distributed OTC brands and a Crop Science portfolio centered on agricultural productivity and sustainability. In 2025, Bayer stated that profitability in Crop Science had become an additional strategic priority, underlining the need for tighter capital discipline in a segment that is both capital intensive and exposed to regulatory pressure. The annual report also highlights continued investment in industrial and R&D assets, especially in Germany. ([reports.bayer.com](https://reports.bayer.com/annual-report-2025/en/to-our-stockholders/investor-information.html?utm_source=openai)) Recent news has been shaped by two main themes: operational normalization and the ongoing glyphosate/Roundup litigation, which continues to affect the risk profile. Bayer disclosed in February 2026 that Monsanto had reached agreement on two significant settlements related to Roundup claims, an important step toward reducing legal uncertainty even if the matter is not fully resolved. At the same time, Bayer reported stronger share-price momentum in 2025 after a historic low at the end of 2024, alongside a higher market capitalization. For international investors, Bayer remains a high-quality industrial and scientific franchise, but one with meaningful exposure to litigation, regulation and strategic execution risk. ([reports.bayer.com](https://reports.bayer.com/annual-report-2025/en/report-on-future-perspectives-and-on-opportunities-and-risks/opportunity-and-risk-report/opportunity-and-risk-status.html?utm_source=openai))